These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Therapeutic targeting of RAS: New hope for drugging the "undruggable". Khan I; Rhett JM; O'Bryan JP Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of RAS: proven and potential vulnerabilities. Zuberi M; Khan I; O'Bryan JP Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838 [TBL] [Abstract][Full Text] [Related]
5. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors. Huynh MV; Campbell SL Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Approaches to RAS Mutation. Scott AJ; Lieu CH; Messersmith WA Cancer J; 2016; 22(3):165-74. PubMed ID: 27341593 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological targeting of RAS: Recent success with direct inhibitors. O'Bryan JP Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101 [TBL] [Abstract][Full Text] [Related]
8. Overcoming Resistance to Drugs Targeting Jiao D; Yang S Innovation (Camb); 2020 Aug; 1(2):. PubMed ID: 32939510 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in cancer drug discovery targeting RAS. Wilson CY; Tolias P Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872 [TBL] [Abstract][Full Text] [Related]
10. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Stalnecker CA; Der CJ Sci Signal; 2020 Mar; 13(624):. PubMed ID: 32209699 [TBL] [Abstract][Full Text] [Related]
11. The current state of the art and future trends in RAS-targeted cancer therapies. Punekar SR; Velcheti V; Neel BG; Wong KK Nat Rev Clin Oncol; 2022 Oct; 19(10):637-655. PubMed ID: 36028717 [TBL] [Abstract][Full Text] [Related]
12. gRASping the redox lever to modulate cancer cell fate signaling. Foo CHJ; Pervaiz S Redox Biol; 2019 Jul; 25():101094. PubMed ID: 30638892 [TBL] [Abstract][Full Text] [Related]
13. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Schulze CJ; Seamon KJ; Zhao Y; Yang YC; Cregg J; Kim D; Tomlinson A; Choy TJ; Wang Z; Sang B; Pourfarjam Y; Lucas J; Cuevas-Navarro A; Ayala-Santos C; Vides A; Li C; Marquez A; Zhong M; Vemulapalli V; Weller C; Gould A; Whalen DM; Salvador A; Milin A; Saldajeno-Concar M; Dinglasan N; Chen A; Evans J; Knox JE; Koltun ES; Singh M; Nichols R; Wildes D; Gill AL; Smith JAM; Lito P Science; 2023 Aug; 381(6659):794-799. PubMed ID: 37590355 [TBL] [Abstract][Full Text] [Related]
14. RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site. Haza KZ; Martin HL; Rao A; Turner AL; Saunders SE; Petersen B; Tiede C; Tipping K; Tang AA; Ajayi M; Taylor T; Harvey M; Fishwick KM; Adams TL; Gaule TG; Trinh CH; Johnson M; Breeze AL; Edwards TA; McPherson MJ; Tomlinson DC Nat Commun; 2021 Jun; 12(1):4045. PubMed ID: 34193876 [TBL] [Abstract][Full Text] [Related]
15. RAS-targeted therapies: is the undruggable drugged? Moore AR; Rosenberg SC; McCormick F; Malek S Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145 [TBL] [Abstract][Full Text] [Related]
17. Progress on Covalent Inhibition of KRAS(G12C). Westover KD; Jänne PA; Gray NS Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837 [TBL] [Abstract][Full Text] [Related]
18. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations. Burge RA; Hobbs GA Adv Cancer Res; 2022; 153():29-61. PubMed ID: 35101234 [TBL] [Abstract][Full Text] [Related]
19. More to the RAS Story: KRAS Lietman CD; Johnson ML; McCormick F; Lindsay CR Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303 [TBL] [Abstract][Full Text] [Related]
20. Drugging K-Ras Ni D; Li X; He X; Zhang H; Zhang J; Lu S Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]